CDC STACKS serves as an archival repository of CDC-published products including scientific findings, journal articles, guidelines, recommendations, or other public health information authored or co-authored by CDC or funded partners.
As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.
i
Live Attenuated Influenza Vaccination Prior To Age 3 Years and Subsequent Development of Asthma: A 14-Year Follow-Up Study
-
May 2018
-
-
Source: Pediatr Infect Dis J. 37(5):383-386
[PDF-132.54 KB]
Details:
-
Alternative Title:Pediatr Infect Dis J
-
Personal Author:
-
Description:Background
Live-attenuated influenza vaccines (LAIVs) are not licensed in children <2 years because of a wheezing safety signal that has not been fully elucidated. In 2000, the Kaiser Permanente Vaccine Study Center conducted a placebo controlled randomized clinical trial (RCT) of LAIV in children. As many of these children were still enrolled in Kaiser Permanente in 2014, we could assess the possible long-term association between LAIV and subsequent asthma diagnosis.
Methods
We identified all children who were originally enrolled into the LAIV RCT at < 3 years of age. We followed subjects until disenrollment from the health plan, a first diagnosis of asthma, or through the end of the study period in 2014. Asthma was defined by a first ICD-9-CM code (493.*) assigned at an outpatient or emergency department encounter. We performed a survival analysis of time to first asthma diagnosis among children receiving LAIV or placebo with a Cox proportional hazards model.
Results
We identified 1151 children in the original RCT who were aged 12 through 35 months at time of enrollment and who had received 2 doses of LAIV or placebo. A total of 767 (66.7%) RCT participants were still KPNC members in 2014. There was no evidence of differential drop-out by treatment group. The hazard ratio for new onset asthma for LAIV recipients compared to placebo was 1.1 (95% confidence interval 0.88–1.41, p=0.38).
Conclusions
We found no evidence of increased risk of subsequent asthma diagnosis among children < 3 years who received LAIV compared to placebo.
-
Subjects:
-
Source:
-
Pubmed ID:28914750
-
Pubmed Central ID:PMC5847407
-
Document Type:
-
Funding:
-
Volume:37
-
Issue:5
-
Collection(s):
-
Main Document Checksum:
-
Download URL:
-
File Type:
